Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

A Study of Fianlimab, Cemiplimab, and Ipilimumab in People with Melanoma

Trial Status: active

This phase II trial tests how well fianlimab, cemiplimab and ipilimumab works to treat patients with melanoma that has spread to nearby tissue or lymph nodes (locally advanced), that cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site) to other places in the body (metastatic) and that has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as fianlimab, cemiplimab and ipilimumab may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving fianlimab, cemiplimab and ipilimumab may be an effective treatment for patients with refractory, locally advanced, unresectable or metastatic melanoma.